Bank of New York Mellon
TCRX icon

Bank of New York Mellon’s TScan Therapeutics TCRX Stock Holding History

Bank of New York Mellon’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-88,142
Closed -$122K – 4265
2025
Q1 		$122K Sell
88,142
-172
-0.2% -$372 ﹤0.01% 3978
2024
Q4 		$268K Hold
88,314
– – ﹤0.01% 3841
2024
Q3 		$440K Sell
88,314
-28,344
-24% -$171K ﹤0.01% 3590
2024
Q2 		$682K Buy
+116,658
New +$919K ﹤0.01% 3398
2024
Q1 		– Sell
-16,670
Closed -$97.2K – 4310
2023
Q4 		$97.2K Buy
+16,670
New +$76.3K ﹤0.01% 4091

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Bank of New York Mellon's TCRX Position: Q2 2025 in Review

Bank of New York Mellon sold out of TScan Therapeutics (TCRX) in Q2 2025, closing a stake of 88,142 shares — an estimated $122K sold.

Bank of New York Mellon first reported a position in TCRX in Q4 2023 and held it in 5 quarters. The position peaked at $682K in Q2 2024. 81 funds tracked by Wall St. Rank hold TCRX as of Q2 2025.

  • Bank of New York Mellon reported no remaining TScan Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Bank of New York Mellon sold 88,142 TScan Therapeutics shares in Q2 2025, an estimated $122K.
  • Bank of New York Mellon first reported a position in TScan Therapeutics in Q4 2023 and held it in 5 quarters.
  • Bank of New York Mellon's TScan Therapeutics position peaked at $682K in Q2 2024.
  • 81 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2025.

Based on Bank of New York Mellon's 13F filing for Q2 2025, filed 5 Aug 2025.